Review Article

Oral Chinese Herbal Medicine as an Adjuvant Treatment for Chemotherapy, or Radiotherapy, Induced Myelosuppression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bonan Hou,1 Rui Liu,1 Zhen Qin,2 Dan Luo,3 Qi Wang,3 and Shuiqing Huang1

1School of Basic Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
2Department of Pharmacology, Guiyang Medical University, Guiyang, Guizhou, China
3Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

Correspondence should be addressed to Qi Wang; wqitcm@qq.com and Shuiqing Huang; hsq@gzucm.edu.cn

Received 3 November 2016; Revised 8 February 2017; Accepted 7 March 2017; Published 10 August 2017

Objective. Myelosuppression is a common side effect in cancer patients receiving chemotherapy or radiotherapy. Chinese herbal medicine (CHM) has shown promise in alleviating myelosuppression. Method. We searched for randomized controlled trials (RCTs) from seven databases without language restriction. We included RCTs in adults, in which hematological toxicity was measured according to WHO criteria and control group underwent chemotherapy and/or radiotherapy and the treatment group was given oral CHM. Results. We searched 1021 articles from the date of databases inception to October 7, 2016. We selected 14 articles for the final analysis. Pooled data showed that CHM significantly decreased the suppression rate of leukocytes, neutrophils, hemoglobin, and platelets compared with the control group, particularly in grade III-IV toxicity (leukocytes: RR = 0.43, 95% CI = 0.33–0.56; neutrophils: RR = 0.39, 95% CI = 0.27–0.58; hemoglobin: RR = 0.33, 95% CI = 0.18–0.61; platelets: RR = 0.61, 95% CI = 0.39–0.95). Conclusions. CHM as an adjuvant can alleviate myelosuppression induced by chemotherapy or radiotherapy, reduce grade III-IV toxicity, and maintain therapeutic dose and treatment cycle. However, due to heterogeneity and publication bias, the results should be interpreted with caution and validated by conducting strictly designed multicenter RCTs of high quality and large scale.

1. Introduction

Myelosuppression, also known as bone marrow (BM) suppression or myelotoxicity, is the major side effect of chemotherapy and radiotherapy. Blood originates in the BM [1] and blood cells have limited life [2]. Once myelosuppression is induced, BM is unable to maintain normal levels of blood cells, which results in a series of complications, such as anemia, infection, and tendency of hemorrhage. Moreover, chemotherapy induces dose-limiting myelosuppression toxicity, but dose reductions would affect treatment efficacy. Therefore, myelosuppression should be addressed while considering chemotherapy or radiotherapy.

It is vital to improve survival rate of cancer patients being treated for anemia, infection, and other complications. However, some treatments could cause adverse effects. For example, G-CSF causes shock or chronic fibrous pneumonia and repetitive platelet transfusion leads to formation of alloantibody [3]. Therefore, it is crucial to find safe agents that can reduce myelosuppression and improve survival rate of patients receiving chemotherapy or radiotherapy. In recent years, Chinese herbal medicine (CHM) has shown promise in this regard.

Studies on CHM preventing myelosuppression have been inconclusive or conflicting. Currently, it is difficult to make the clinical decision of administering CHM as an adjuvant in chemotherapy or radiotherapy. A similar systematic review was published [4], which revealed effects of various CHMs in myelosuppression prevention. To provide better insights for making appropriate clinical decisions, we aimed to review the effects of oral CHM as we believe that the effects vary with the route of administration.
Table 1: Recommendation for grading of WHO criteria.

|                        | Grade 0  | Grade I  | Grade II | Grade III | Grade IV |
|------------------------|----------|----------|----------|-----------|----------|
| **Hemoglobin (HB)**    | ≥11.0 g/100 ml | 9.5–10.9 g/100 ml | 8.0–9.4 g/100 ml | 6.5–7.9 g/100 ml | <6.5 g/100 ml |
|                        | ≥110 g/l | 95–109 g/l | 80–94 g/l | 65–79 g/l | <65 g/l |
|                        | ≥6.8 mmol/l | 5.6–6.7 mmol/l | 4.95–5.8 mmol/l | 4.0–4.9 mmol/l | <4.0 mmol/l |
| **Leukocytes (WBC)**   | ≥4.0 | 3.0–3.9 | 2.0–2.9 | 1.0–1.9 | <1.0 |
| (1000/mm³)             | ≥2.0 | 1.5–1.9 | 1.0–1.4 | 0.5–0.9 | <0.5 |
| **Platelets (PLT)**    | >100 | 75–99 | 50–74 | 25–49 | <25 |
| (1000/mm³)             |          |          |          |          |          |

In this study, our objective was to minimize clinical heterogeneity and pool high-quality studies to generate robust evidence regarding the potential therapeutic value of CHM in preventing myelosuppression. This meta-analysis was reported and performed in accordance with PRISMA guidelines (SI File in Supplementary Material available online at https://doi.org/10.1155/2017/3432750).

2. Methods

2.1. Inclusion and Exclusion Criteria. We included studies that conducted randomized controlled trials (RCTs) and in which patients were over 18 years of age, control group was treated with radiotherapy or drug therapy and treatment group was treated with CHM along with radiotherapy or drug therapy, and hematological toxicity was measured mainly according to World Health Organization (WHO) criteria [19] (Table 1). The exclusion criteria were as follows: (1) assessment of hematological toxicity by total bone marrow inhibition rate, rather than WHO criteria; (2) treatment with acupuncture, intravenous CHM, CHM granules, patented CHM drug, or CHM extract; (3) treating patients in control group with CHM and not chemotherapy or radiotherapy; (4) treating patients in treatment group with more than two types of CHM; and (5) methodological quality score of less than 3 points on Jadad scale.

2.2. Search Strategy. We systematically searched databases, including China Academic Journal Network Publishing Database (CAJID), China Biology Medicine disc (CBMdisc), China Doctoral Dissertations Full-text Database (CDDFD), China Master's Dissertations Full-text Database (CMFD), PubMed, Cochrane, and EMBASE, for relevant articles published from the date of the databases inception to October 7, 2016. There were no language restrictions. As part of search strategy, we used a combination of the following terms: "Chinese herbal medicine" ("Chinese medicine," "traditional Chinese medicine (TCM)," "Chinese herbal medicine," "Chinese herbal drug," "traditional herbal medicine," "herbal medicine," "traditional Japanese medicine," "traditional medicine," "ethnomedicine," "folk medicine," "folk remedies," "indigenous medicine," "primitive medicine," "materia medica," "homeopathic remedies," "traditional East Asian medicine," "traditional Far Eastern medicine," "Far East medicine," "Oriental medicine," "Korean medicine," "Tibetan medicine," "herb," "herbaceous agent," "medicinal plant," "medicinal herbs," "medicinal plant product," "plant preparation," "herbal preparation," "botanic," "botany," "Kampo," "traditional Mongolian medicine," "Mongolian folk medicine," "Mongolian medicine," "phytotherapy," "herb therapy," "herbal therapy," "ethnopharmacology," "alternative medicine," "alternative therapy," "complementary therapy," "complementary medicine," "TCM," "CHM," "tang," or "decoction") [20] and "radiotherapy" ("drug therapy" or "chemotherapy") and "randomized controlled trial" ("randomized controlled trial," "controlled clinical trial," "randomized controlled trials," "random allocation," or "random").

Gray articles were identified by searching Chinese Clinical Trial Register (ChiCTR), the American Society of Clinical Oncology (ASCO), and Google. In addition, we manually searched reference lists of relevant articles.

2.3. Study Selection and Data Extraction. Studies were selected by two researchers (BNH, RL). First, titles were read and irrelevant or duplicate articles were removed. Second, editorials, opinions, or case reports were excluded through abstract screening. Third, after reading the full text, on the basis of inclusion and exclusion criteria, articles were filtered. BNH and RL selected articles independently and any disagreement was resolved by discussion. If they still disagreed, the third reviewer (SQH) intervened to resolve the disagreement.

Data were extracted by two researchers (DL, ZQ) separately, including authors, years, cancer type, number of patients (including number of dropouts or withdrawals), intervention, outcome, detailed content on CHM, and Jadad score. The extracted data were verified by the third author (QW). Disagreements were resolved by face-to-face discussion among the three authors.

2.4. Quality Assessment. Methodological qualities of the included RCT trials were assessed using Jadad scale [21]. Two
Evidence-Based Complementary and Alternative Medicine

3. Results

3.1. Article Selection. We retrieved 1021 articles through databases and Internet search as well as manual search. After removing duplicates, 978 articles were identified, and, after reading titles, 570 irrelevant articles were excluded and 408 potentially relevant articles were included. Following abstract screening, 3 reviews and 1 case report were excluded. Finally, through a conscientious review of full text, 390 articles were removed, including studies of low methodological quality (90 articles); studies with duplicate (1 article), data inconsistency (1 article), or no RCT (35 articles); studies that lack sufficient data (260 articles); and studies that used intravenous CHM (1 article), CHM granules (1 article), or patented CHM drug (1 article). Thus, 14 articles [5–18] were included. Figure 1 presents a flow chart of the study selection process.

![Flow chart of article search.](image-url)
3.2. Characteristics of Articles Included. In total, 1275 patients (14 articles) were considered, 65 dropped out or withdrew [5–7, 9, 11–18], 71 lacked myelosuppression data [8], and 62 took CHM at different time points [18]. Finally, 1077 patients were included. Table 2 shows the characteristics of the articles included. Cancers included ovarian cancer (3 articles), breast cancer (3 articles), throat cancer (1 article), non-small-cell lung cancer (6 articles), and colorectal cancer (1 article). All articles were graded at least 3 on Jadad scale and one was graded 5. CHM was administered to patients twice a day during chemotherapy and radiotherapy.

3.3. Myelosuppression

3.3.1. Effects of CHM on WBC. The number of patients in CHM group at toxic grades III-IV and I–IV in whom WBC inhibition was observed was less than that in the control group (RR = 0.43, 95% CI = 0.33–0.56, P < 0.001; RR = 0.74, 95% CI = 0.67–0.81, P < 0.001), with no heterogeneity in grades III-IV (I² = 0%, P = 0.978). However, in grades I–IV, there was significant heterogeneity among the articles (I² = 49.5%, P = 0.026). For searching possible sources of heterogeneity, we excluded articles one by one. After dropping “Chan 2011,” heterogeneity was I² = 20.3%, P = 0.250 (random effects model) or I² = 24.1%, P = 0.214 (fixed effects model) (Figure 2).

3.3.2. Effect of CHM on Neutrophils. The suppression rate of neutrophils in patients belonging to the CHM group at toxic grades III-IV was only 39% of that in the control group (RR = 0.39, 95% CI = 0.27–0.58, P < 0.001), and, at toxic grades I–IV, the rate was 76% of that in the control group (RR = 0.76, 95% CI = 0.62–0.93, P = 0.008). There was no heterogeneity in toxic grades III-IV (I² = 42.8%, P = 0.120); however, in grades I–IV, significant heterogeneity was observed among articles (I² = 47.1%, P = 0.092). For searching possible sources of heterogeneity, we excluded articles one by one. After dropping “Chan 2011,” heterogeneity was I² = 0.0%, P = 0.709 (random effects model) or I² = 0.0%, P = 0.709 (fixed effects model) (Figure 3).

3.3.3. Effect of CHM on HB. In the CHM group, the suppression of HB decreased by 67% in patients at toxic grades III-IV and 30% in patients at toxic grades I–IV (RR = 0.41, 95% CI = 0.23–0.72, P = 0.002; RR = 0.68, 95% CI = 0.54–0.87, P = 0.002), compared with the control group, with no heterogeneity in grades III-IV (I² = 0%, P = 0.570) but with significant heterogeneity in grades I–IV (I² = 64.2%, P = 0.007). On further exclusion of articles one by one, we found that dropping of “Chan 2011” decreased heterogeneity [I² = 28.9%, P = 0.208 (random effects model) and I² = 33.9%, P = 0.169 (fixed effects model)] (Figure 4).

3.3.4. Effect of CHM on PLT. In the CHM group, the number of patients at toxic grades III-IV and I–IV in whom PLT inhibition was observed was less than that in the control group (RR = 0.54, 95% CI = 0.34–0.85, P = 0.028; RR = 0.69, 95% CI = 0.55–0.88, P = 0.003), with no heterogeneity in grades III-IV (I² = 0%, P = 0.780) and I–IV (I² = 27.8%, P = 0.206) (Figure 5).

3.3.5. Subgroup Analysis of WBC at Toxic Grades II–IV. According to the theory for TCM, we divided 14 articles by the treatment into 4 subgroups: yiqi-jianpi-huoxue-jiedu, yiqi-yangyn-huoxue-jiedu, jianpi-yijing, and other. Result indicated that all 4 types of treatments were effective (RR = 0.322, 95% CI = 0.106–0.979, P = 0.046; RR = 0.397, 95% CI = 0.242–0.650, P < 0.001; RR = 0.438, 95% CI = 0.294–0.654, P < 0.001; RR = 0.494, 95% CI = 0.291–0.839, P = 0.009), with no heterogeneity (Figure 6).

3.4. Publication Bias and Sensitivity Analysis. There were 4 meta-analyses including no less than 10 articles; of them, one showed the presence of a publication bias (Table 3). The remaining articles had no evidence to indicate the presence of potential publication bias.

We analyzed sensitivity by changing the analysis model (Table 4). The RR of pooling data was robust.

4. Discussion

We performed meta-analysis of CHM as an adjuvant treatment for chemotherapy- or radiotherapy-induced myelosuppression. The results suggested that oral CHM is effective in protecting WBC, neutrophils, HB, and PLT. Begg, Egger, and Harbord tests revealed the presence of publication bias in WBC (toxic grades I–IV) analysis. The sensitivity analysis indicated that all analyses were robust with no evident publication bias.

In this meta-analysis, the curative effect for grades III-IV was better than that for I–IV. The myelosuppression rate at toxic grades I-II showed no significant difference among the CHM treatment, no CHM treatment, and placebo treatment groups (supplementary document). Result suggested that toxic grades I-II were responsible for the difference between toxic grades III-IV and toxic grades I–IV. We further analyzed the results for toxic grades I-II. In general, toxic grades III-IV were the index for the clinical treatment of patients showing myelosuppression, in whom treatment for toxic grade II or lower mainly focuses on symptomatic therapy. These results were similar to those in published articles about treating myelosuppression inpatients mostly at toxic grades III-IV. Source data from the 14 articles was insufficient to confirm our hypothesis about toxic grades I-II. We did not analyze toxic grades I, II, III, IV, and II-I, as they provided no extra information.

The main finding of our meta-analysis was different from that of the previous one [4], which indicated that CHM significantly protected peripheral WBC, but not peripheral HB or PLT. We found that CHM can protect not only peripheral WBC, but also HB, PLT, and neutrophils. The previous study analyzed continuous data from 8 articles but did not pool data for neutrophils. Our meta-analysis pooled ranked data for WBC, neutrophils, HB, and PLT from 14 articles. Moreover, the referenced articles were different. We did not include the articles in the previous meta-analysis, as seven of eight articles did not meet our inclusion criteria...
Table 2: Characteristics of the articles included.

| Authors          | Years | Kind of cancer     | Number of patients/dropout or withdrawal | Intervention (C/T)<sup>a</sup> | Outcome                                                                 | Detailed content of CHM | Jadad score |
|------------------|-------|--------------------|------------------------------------------|-------------------------------|------------------------------------------------------------------------|-------------------------|------------|
| Chan et al. [5]  | 2011  | Ovarian cancers    | 81/27                                    | Chemotherapy and placebo/chemotherapy and CHM | QLQ-C30<sup>b</sup>; the side effects of chemotherapy (the WHO criteria); immune function | BASIC FORMULA           | 5          |
| Chen et al. [6]  | 2015  | Breast cancer      | 60/3                                     | Chemotherapy/chemotherapy and CHM | The side effects of chemotherapy; KPS score; immune function; serum tumor markers | Shuganjianpi decoction | 3          |
| Chen [7]         | 2012  | Ovarian cancers    | 60/1                                     | Chemotherapy/chemotherapy and CHM | The side effects of chemotherapy; KPS score; TCM syndrome index; QOL<sup>c</sup> | Yiliu decoction        | 3          |
| Chen et al. [8]  | 2012  | Throat cancer      | 156/0                                    | Chemoradiotherapy/chemoradiotherapy and CHM | The side effects of chemotherapy (the WHO criteria); KPS score; survival time | Qingliulianghou decoction | 3          |
| Huang et al. [9] | 2011  | Non-small-cell lung cancer | 60/3                                | Chemotherapy/chemotherapy and CHM | The side effects of chemotherapy (the WHO criteria); TCM syndrome index; KPS score | Yiqiyangyin decoction | 3          |
| Li [10]          | 2015  | Colorectal cancer  | 62/0                                     | Chemotherapy/chemotherapy and CHM | The side effects of chemotherapy (the WHO criteria) | Yiqiyangxue decoction | 3          |
| Jun [11]         | 2008  | Non-small-cell lung cancer | 129/14                               | Chemoradiotherapy/chemoradiotherapy and CHM | The side effects of chemotherapy (the WHO criteria); KPS score; QOL; the side effects of chemotherapy | Fuzhengkangai decoction | 3          |
| Liu [12]         | 2008  | Ovarian cancers    | 50/2                                     | Chemotherapy/chemotherapy and CHM | The side effects of chemotherapy; use of GCSF<sup>d</sup>; safety evaluation | Wenshen Shengbai decoction | 3          |
| Lu et al. [13]   | 2014  | Breast cancer      | 120/2                                    | Chemotherapy and placebo/chemotherapy and CHM | The side effects of chemotherapy (the WHO criteria); UICC; the side effects of chemotherapy (the WHO criteria); KPS score; survival time; weight | Fuzhengjiedu decoction | 3          |
| Sun [14]         | 2011  | Non-small-cell lung cancer | 60/1                                | Chemotherapy/chemotherapy and CHM | The side effects of chemotherapy (the WHO criteria); immune function | Fuzhengxiaoyan decoction | 3          |
| Wu [15]          | 2016  | Breast cancer      | 70/1                                     | Chemotherapy/chemotherapy and CHM | The side effects of chemotherapy (the WHO criteria); immune function; UICC; the side effects of chemotherapy (the WHO criteria); KPS score; survival time; weight | Fuzhengxiaoyan decoction | 3          |
| Xu et al. [16]   | 2007  | Non-small-cell lung cancer | 120/4                                | Chemotherapy/chemotherapy and CHM | QOL; the side effects of chemotherapy (the WHO criteria); survival time; TCM syndrome index; KPS score; immune function; the side effects of chemotherapy | Kangliuzengxiao decoction and feiyanning decoction | 3          |
| Xu et al. [17]   | 2011  | Non-small-cell lung cancer | 120/4                                | Chemotherapy/chemotherapy and CHM | QOL; the side effects of chemotherapy (the WHO criteria); survival time; TCM syndrome index; KPS score; immune function; the side effects of chemotherapy | Kangliuzengxiao decoction and feiyanning decoction | 3          |
| Zhu et al. [18]  | 2011  | Non-small-cell lung cancer | 127/3                                | Chemotherapy/chemotherapy and CHM | QOL; the side effects of chemotherapy (the WHO criteria); survival time; TCM syndrome index; KPS score; immune function; the side effects of chemotherapy | Kangliuzengxiao decoction | 3          |

<sup>a</sup> Control group/treatment group.

<sup>b</sup> Quality of Life Questionnaire C30.

<sup>c</sup> Quality of life.

<sup>d</sup> Granulocyte cell stimulating factor.
Figure 2: Effect of CHM on leukocytes.
and the remaining one was of low methodological quality (Jadad scale < 3 score). In addition, different data style may induce different results. Ranked data reflects the curative effect of treating various patients under serious conditions, rather than a simple summary that would conceal effective treatment, such as continuous data.

To obtain robust results in the present meta-analysis, we included high-quality RCTs using Jadad scale to screen...
**Figure 4: Effect of CHM on hemoglobin.**

(a) HB at toxic grades III-IV

| Study ID       | RR (95% CI) | Events, treatment | Events, control | % weight |
|----------------|-------------|-------------------|-----------------|----------|
| Chan et al. 2011 | 0.93 (0.21, 4.20) | 3/28 | 3/26 | 8.26 |
| Chen 2012      | 0.39 (0.08, 1.84)  | 2/30 | 5/29 | 13.49 |
| Chen et al. 2012 | 0.34 (0.10, 1.14)  | 3/40 | 10/45 | 24.98 |
| Huang et al. 2011 | 0.48 (0.05, 5.03)  | 1/29 | 2/28 | 5.40 |
| Sun 2011       | 0.19 (0.01, 3.87)  | 0/30 | 2/29 | 6.74 |
| Wu 2016        | 0.09 (0.01, 1.58)  | 0/35 | 5/35 | 14.60 |
| Xu et al. 2007 | 1.87 (0.36, 9.80)  | 4/60 | 2/56 | 5.49 |
| Xu et al. 2011 | 0.17 (0.02, 1.40)  | 1/63 | 5/53 | 14.41 |
| Zhu et al. 2011 | 0.20 (0.01, 4.00)  | 0/31 | 2/31 | 6.63 |
| Li 2015        | (Excluded)        | 0/31 | 0/31 | 0.00 |
| Overall (I² = 0.0%, P = 0.570) | 0.41 (0.23, 0.72) | 14/377 | 36/363 | 100.00 |

(b) HB at toxic grades I-IV

| Study ID       | RR (95% CI) | Events, treatment | Events, control | % weight |
|----------------|-------------|-------------------|-----------------|----------|
| Chan et al. 2011 | 0.97 (0.85, 1.10) | 26/28 | 25/26 | 23.24 |
| Chen 2012      | 0.46 (0.26, 0.80)  | 10/30 | 21/29 | 10.80 |
| Huang et al. 2011 | 0.45 (0.20, 1.01)  | 6/29 | 13/28 | 6.49 |
| Li 2015        | 0.57 (0.19, 1.76)  | 4/31 | 7/31 | 3.91 |
| Sun 2011       | 0.24 (0.09, 0.64)  | 4/30 | 16/29 | 4.98 |
| Wu 2016        | 0.77 (0.52, 1.14)  | 18/34 | 24/35 | 15.16 |
| Xu et al. 2007 | 0.74 (0.55, 1.00)  | 31/60 | 39/56 | 18.00 |
| Xu et al. 2011 | 0.75 (0.54, 1.02)  | 31/63 | 35/53 | 17.44 |
| Overall (I² = 64.2%, P = 0.007) | 0.68 (0.54, 0.87) | 130/305 | 180/287 | 100.00 |

Note. Weights are from random effects analysis.
**Evidence-Based Complementary and Alternative Medicine**

| Study ID | RR (95% CI) | Events, treatment | Events, control | % weight |
|----------|-------------|-------------------|----------------|---------|
| Chan et al. 2011 | 1.19 (0.52, 2.74) | 9/28 | 7/26 | 16.78 |
| Chen et al. 2015 | 0.32 (0.01, 7.59) | 0/29 | 1/28 | 3.53 |
| Chen et al. 2012 | 0.38 (0.17, 0.85) | 6/40 | 18/45 | 39.15 |
| Huang et al. 2011 | 0.48 (0.10, 2.43) | 2/29 | 4/28 | 9.41 |
| Li 2015 | 0.33 (0.01, 7.88) | 0/31 | 1/31 | 3.47 |
| Liu 2008 | 0.31 (0.03, 2.74) | 1/25 | 3/23 | 7.22 |
| Sun 2011 | 0.32 (0.01, 7.61) | 0/30 | 1/29 | 3.52 |
| Xu et al. 2007 | 0.47 (0.04, 5.01) | 1/60 | 2/56 | 4.78 |
| Xu et al. 2011 | 0.28 (0.03, 2.62) | 1/63 | 3/53 | 7.53 |
| Zhu et al. 2011 | 1.00 (0.15, 6.66) | 2/31 | 2/31 | 4.62 |
| Overall ($I^2 = 0.0\%$, $P = 0.780$) | 0.54 (0.34, 0.85) | 22/366 | 42/350 | 100.00 |

**Figure 5:** Effect of CHM on platelets.
the methodological quality of articles and excluded studies that treated patients with acupuncture, intravenous CHM, CHM granules, patented CHM drug, or CHM extract, to reduce clinical heterogeneity among articles for comparison with previous meta-analyses. According to the theory for TCM, the herbs used in the 14 articles belong to yiqi-jiedu (tonifying qi and disintoxication) treatment. Our meta-analysis only included oral CHM; the results showed low heterogeneity (WBC, HB, and neutrophils at toxic grades I–IV) and homogeneity, which suggested that the yiqi-jiedu treatment could be the same treatment. To validate our hypothesis, we performed subgroup analysis of WBC at toxic grades III-IV (only WBC at toxic grades III-IV was included in all 14 articles). The 14 articles were divided by the herb into 4 subgroups, which means that yiqi-jiedu treatment was also subdivided into 4 treatments. The results were similar. Moreover, sensitivity analysis based on change of analysis model did not fundamentally alter most of the pooled results.

In Asia, CHM has long been used in the treatment of chronic diseases and cancer as a primary therapy or adjuvant therapy. Nevertheless, one may assume that CHM played the role of placebo. Two of the 14 articles reported that the control group received placebo [5, 13], which was indistinguishable in terms of taste and appearance from the study medication. There was no significant placebo effect. Furthermore, several high-quality articles suggested that CHM was not a potential placebo [26, 27].

Some articles indicated that there was a positive interaction between the administered CHM and concomitant chemotherapy or radiotherapy [28, 29]. The administration
of CHM along with chemotherapy may offer some immediate benefits to patients such as improvement of tumor response and quality of life. However, in myelosuppression, there was a negative interaction between the two therapies. The therapeutic mechanism of CHM as an adjuvant treatment for myelosuppression remains unclear. The dominant opinion about the effectiveness of CHM is that it alleviates myelosuppression by multitarget treatments [30, 31].

Neutropenia is a common dose-limiting toxicity that is difficult to treat. Our meta-analysis indicated that oral CHM as an adjuvant can prevent the decrease in neutrophils during chemotherapy and radiotherapy, suggesting that CHM maintains the therapeutic dose and treatment cycle. Furthermore, CHM can prevent the decrease in WBC, HB, and PLT. Compared with the other treatments, the advantage of CHM is that it evidently improves the curative effect of chemotherapy and radiotherapy.

Our meta-analysis has some limitations. First, CHM treatment is an individualized therapy. According to the theory for TCM, the difference in individualized therapy should be based on different diseases or symptoms. In our meta-analysis, the treatments in 14 articles belonged to yiqi-jiedu. Furthermore, our results show low heterogeneity and homogeneity and the results of subgroup analysis are similar. Although clinical heterogeneity is low, division into 4 subgroups could improve the robustness of the results. However, as the present research is limited, it was difficult to perform further analysis. Second, our meta-analysis did not include results for lymphocytes. Neutrophils:lymphocyte ratio is also an important hematomatological toxicity predictive index. However, there are no relevant articles meeting our inclusion criteria. Third, we included 5 types of cancers, with different drug sensitivity. Fourth, only two articles mention the concrete blind method. Fifth, we could not assess the impact of CHM treatment on other clinically meaningful endpoints, such as overall survival and quality of life, due to the limited number of reports available.

Future studies could focus on the following points. First, drugs for tonifying qi and disintoxication play an important role in the treatment. Therefore, these types of drugs should be studied, as further subdividing treatment could provide more robust results, new therapy ideas, or drugs against myelosuppression. Second, better blind methods should be designed to improve methodological quality. Third, further studies can focus on other clinical endpoints, such as quality of life, survival, and length of stay, as there is a lack of high-quality studies demonstrating the correlation between CHM and these endpoints.

5. Conclusions

Evidence obtained from this study suggests that CHM can be used as an adjuvant to alleviate myelosuppression induced by chemotherapy or radiotherapy and, in particular, reduce grade III-IV toxicity. However, due to heterogeneity and publication bias in the partial results of this meta-analysis (WBC at toxic grades I–IV, neutrophils at toxic grades I–IV), the results should be interpreted with caution and validated by conducting strictly designed multicenter RCTs of high quality and large scale.

Disclosure

Bonan Hou and Rui Liu are co-first authors.
Conflicts of Interest

The authors do not have any financial or nonfinancial conflicts of interest.

Authors’ Contributions

Bonan Hou and Rui Liu have contributed to this work equally. Qi Wang and Shuiqing Huang contributed to this work equally and should be considered as co-corresponding authors.

Acknowledgments

The authors thank Junan Hou and Dr. Zhenyu Cao for modification of language. This study was supported by Nature Scientific Foundation of China (NSFC) (nos. 81373522 and 81273817).

References

[1] H. Lu, S. Zhu, L. Qian et al., “Activated expression of the chemokine Mig after chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity,” Blood, vol. 119, no. 21, pp. 4868–4877, 2012.
[2] W. Han, Y. Yu, and Y. L. Xin, “Local signals in stem cell-based bone marrow regeneration,” Cell Research, vol. 16, no. 2, pp. 189–195, 2006.
[3] L. Heuer and D. Blumenberg, “Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets,” Blood Coagulation and Fibrinolysis, vol. 16, no. 4, pp. 287–290, 2005.
[4] Y. Jia, H. Du, M. Yao et al., “Chinese herbal medicine for myelosuppression induced by chemotherapy or radiotherapy: A systematic review of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 690976, 2015.
[5] K. K. L. Chan, T. J. Yao, B. Jones et al., “The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: A double-blind placebo-controlled randomized trial with immunological monitoring,” Annals of Oncology, vol. 22, no. 10, pp. 2241–2249, 2011.
[6] H. W. Chen, W. Shi, and X. G. Li, “Effect of Chinese Herbal Compound Combining Chemotherapy on Recurrence Breast Cancer,” Liaoning Journal of traditional Chinese Medicine, vol. 42, no. 5, pp. 1003–1005, 2015.
[7] L. L. Chen, A Study of Effect Yiliu Decocotion Combined with Chemotherapy on Quantity of Life of Qi Deficiency and Blood Stasis Type Postoperative Ovarian Carcinoma Patients, Fujian University of Traditional Chinese Medicine, 2012.
[8] W.-J. Chen, B. Wang, and X.-L. Han, “[Adjunctive therapy of hypopharyngeal carcinoma by Qingliu Lianghou Recipe].” Zhongguo Zhong xi yizhi hua zhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yizhi hua zhi, vol. 32, no. 7, pp. 892–895, 2012.
[9] Y. H. Huang, A. J. Hu, Y. Zhou, and L. Gao, “Study on Yiqiyangyin Decoction combine with GP chemotherapy in advanced non-small cell lung cancer,” Journal of New Chinese Medicine, vol. 43, no. 9, pp. 47–49, 2011.
[10] M. F. Li, “To observe the curative effect of Yiqi Yangxue Decoction on bone marrow suppression after chemotherapy,” Shaanxi traditional Chinese Medicine, vol. no. 8, pp. 960–961, 2015.
[11] L. Jun, “Clinical Research on 58 Cases of Advanced Non-small Cell Lung Cancer Treated by the Integrated TCM and Western Medicine [],” Henan Traditional Chinese Medicine, vol. 6, p. 022, 2008.
[12] Y. Liu, ‘clinical study on oophoroma after treated with fuzheng- quyu decoction combined with chemotherapy,’ Heilongjiang University Of Chinese Medicine, 2008.
[13] Q. Z. L. J. Lu, K. Li, Q. Ji, and Y. J. Xue, “Clinical Observation of Wenshen Shengbai Decoction for Myelosuppression Induced by Chemotherapy for Postoperative Breast Cancer,” Journal of Shanghai University of Traditional Chinese Medicine, vol. 28, no. 3, pp. 29–31, 2014.
[14] Q. Sun, “Clinical observation of traditional Chinese medicine combined with chemotherapy in the treatment of advanced non small cell carcinoma,” Hainan Medical Journal, vol. 22, no. 15, pp. 31–33, 2011.
[15] X. Wu, “treatment of recurrent and metastatic breast cancer with combination of NP and Fuzhengxiaoyan decoction,” Jilin Journal of Traditional Chinese Medicine, vol. no. 09, pp. 911–915, 2016.
[16] Z. Xu, C. Jin, and D. Shen, “Clinical study on treatment of advanced non-small-cell lung cancer with Chinese herbal medicine in different stages combined with chemotherapy,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 27, no. 10, pp. 874–878, 2007.
[17] Z. Y. Xu, C. J. Jin, C. C. Zhou et al., “Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 7, pp. 1117–1122, 2011.
[18] L.-M. Zhu, H. Zhang, H. Zhou, C.-F. Pan, K.-P. Shen, and Z.-Y. Xu, “Time-effect relationship of kangliu zengxiao decoction in reducing chemotherapy-associated adverse reactions in patients with advanced non-small cell lung cancer,” Journal of Shanghai Jiaotong University (Medical Science), vol. 31, no. 6, pp. 797–801, 2011.
[19] World Health Organization, WHO Handbook for Reporting Results of Cancer Treatment, 1979.
[20] S. G. Li, H. Y. Chen, C. S. Ou-Yang et al., “The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 2, Article ID e57604, 2013.
[21] A. R. Jadad, R. A. Moore, D. Carrol et al., “Assessing the quality of reports of randomized clinical trials: Is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996.
[22] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003.
[23] C. B. Begg and M. Mazumdar, “Operating characteristics of a simple, graphical test,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994.
[24] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical journal, vol. 315, pp. 629–634, 1997.
[25] R. M. Harbord, M. Egger, and J. A. Sterne, “A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints,” Statistics in Medicine, vol. 25, no. 20, pp. 3443–3457, 2006.
[26] A. Bensoussan, N. J. Talley, M. Hing, R. Menzies, A. Guo, and M. Ngu, “Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial,” Journal of the American Medical Association, vol. 280, no. 18, pp. 1585–1589, 1998.

[27] T. S. K. Mok, W. Yeo, P. J. Johnson et al., “A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity,” Annals of Oncology, vol. 18, no. 4, pp. 768–774, 2007.

[28] X. Sun, X. Zhang, J.-Y. Nian et al., “Chinese Herbal Medicine as Adjunctive Therapy to Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, 2016.

[29] S. Chen, A. Flower, A. Ritchie et al., “Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review,” Lung Cancer, vol. 68, no. 2, pp. 137–145, 2010.

[30] Q.-Q. Chen, X. Han, W.-M. Wang, L. Zhao, and A. Chen, “Danggui Sini Decoction Ameliorates Myelosuppression in Animal Model by Upregulating Thrombopoietin Expression,” Cell Biochemistry and Biophysics, vol. 71, no. 2, pp. 945–950, 2014.

[31] M. Liu, H. Tan, X. Zhang et al., “Hematopoietic effects and mechanisms of Fufang E’jiao Jiang on radiotherapy and chemotherapy-induced myelosuppressed mice,” Journal of Ethnopharmacology, vol. 152, no. 3, pp. 575–584, 2014.